𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Detection of survivin and p53 in human oral cancer: Correlation with clinicopathologic findings

✍ Scribed by Zakir Khan; Ram P. Tiwari; Rita Mulherkar; Nand K. Sah; Godavarthi BKS Prasad; Braj R. Shrivastava; Prakash S. Bisen


Book ID
102232309
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
366 KB
Volume
31
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Background

Survivin, an inhibitor of apoptosis, is overexpressed in cancer. It has been implicated in both prevention of apoptosis and cell cycle regulation. We investigated the distribution of antiapoptotic protein survivin in 29 oral squamous cell carcinoma (OSCC) and 16 oral premalignant lesions. It has been suggested that wild‐type p53 represses survivin expression. Therefore, we investigated the status of p53 in relation to survivin to determine the potential involvement in oral tumorigenesis.

Methods

Oral cancer tissues were freshly obtained at the time of surgery and classified as per general rules of head and neck cancer (TNM classification). Immunohistochemistry and reverse transcriptase‐polymerase chain reaction were conducted to study the expression of survivin and p53. The Fisher's exact test was employed to determine the association of survivin and p53 with clinicopathologic parameters of the subjects being studied.

Results

Positive staining for survivin was found in 72% OSCC and 44% oral premalignant lesions with no immunoreactions in the corresponding normal tissues. For p53, 59% OSCC, 38% premalignant lesions, and 14% normal tissues were positive. Importantly, about half of the p53‐positive OSCC and premalignant tissues also showed survivin positivity (28% OSCC and 18% premalignant lesions). Further, it is observed that the number of survivin positive cells was significantly higher in the p53‐positive group. Survivin is expressed in a varying proportion of cells, and in majority of patients it was localized in cytoplasm, whereas p53 is strictly restricted to the nucleus. The survivin expression levels in both primary OSCC and premalignant lesions were significantly higher than in normal oral tissues (OSCC, p < .0008; premalignant lesions, p < .04). No significant correlations between survivin and p53 expression with clinicopathologic parameters were found.

Conclusions

Frequent overexpression of apoptosis regulators, survivin and p53, in OSCC as well as in oral premalignant lesions were found. Overexpression of these 2 markers in premalignant lesions suggest a role in early stages of oral carcinogenesis. Β© 2009 Wiley Periodicals, Inc. Head Neck, 2009


πŸ“œ SIMILAR VOLUMES


Evaluation of P-glycoprotein expression
✍ Ranju Ralhan; Murli Narayan; Poonam Salotra; Nootan K. Shukla; Shyam S. Chauhan πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 309 KB πŸ‘ 1 views

To determine whether the multidrug-resistance-gene product phospho-glycoprotein (P-gp) is implicated in progression of oral tumours and/or drug resistance, the expression of P-gp was examined in different stages of oral oncogenesis using monoclonal antibody C-219. Cryosections from normal (41 cases)

Expression of p53 protein in laryngeal s
✍ V. Gorgoulis; G. Rassidakis; C. Kittas; A. Giatromanolaki; C. Barbatis; A. Karam πŸ“‚ Article πŸ“… 1994 πŸ› Springer 🌐 English βš– 1012 KB

In order to evaluate the expression of p53 protein in 28 premalignant and 40 malignant squamous cell proliferations of the larynx and its relationship to tobacco consumption, human papillomavirus infection and differentiation grade of the lesions, p53 expression was examined by means of a microwave

Immunohistochemical analysis of p53 in c
✍ Hirotsugu Tomoda; Yoshihiro Kakeji πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 353 KB

The overexpression of the tumor suppressor gene p53 was investigated immunohistochemically in 144 cases of primary colorectal cancer and in 8 cases with cancer in the corresponding metastatic lymph nodes. Abnormalities in p53 expression were found in 36 cases (25%) of the 144 primary cancer cases. I